BRAINP Stock Overview
Brain+ A/S develops digital therapeutics for Alzheimer’s and dementia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Brain+ A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.0.13 |
| 52 Week High | kr.1.00 |
| 52 Week Low | kr.0.11 |
| Beta | 0 |
| 1 Month Change | -6.79% |
| 3 Month Change | -34.42% |
| 1 Year Change | -82.27% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRAINP | DK Healthcare Services | DK Market | |
|---|---|---|---|
| 7D | -2.6% | -2.5% | -1.4% |
| 1Y | -82.3% | -2.0% | 21.5% |
Return vs Industry: BRAINP underperformed the Danish Healthcare Services industry which returned -2% over the past year.
Return vs Market: BRAINP underperformed the Danish Market which returned 21.5% over the past year.
Price Volatility
| BRAINP volatility | |
|---|---|
| BRAINP Average Weekly Movement | 12.9% |
| Healthcare Services Industry Average Movement | 6.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DK Market | 9.1% |
| 10% least volatile stocks in DK Market | 3.0% |
Stable Share Price: BRAINP's share price has been volatile over the past 3 months.
Volatility Over Time: BRAINP's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Kim Baden-Kristensen | www.brain-plus.com |
Brain+ A/S develops digital therapeutics for Alzheimer’s and dementia. The company’s product pipeline includes cognitive stimulation therapy (CST) - Therapist Companion, an application that enables therapists to deliver CST while saving significant preparation time; CST - Home Companion, a digital health application to provide repeat exposure to the CST program in an at-home setting during and after participation in a therapist facilitated CST program; CST - Home Care, a solution to enable people with dementia to continue to receive maintenance benefits from CST therapy after completion of the seven-week basic CST group program; and CST for mild cognitive impairment (MCI), a solution for individuals with MCI, offering an adapted version of CST to address their unique needs. It also develops Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, a memory test designed to identify early signs of Alzheimer’s disease.
Brain+ A/S Fundamentals Summary
| BRAINP fundamental statistics | |
|---|---|
| Market cap | kr.11.93m |
| Earnings (TTM) | -kr.462.19k |
| Revenue (TTM) | kr.6.08m |
0.0x
P/S Ratio0.0x
P/E RatioIs BRAINP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRAINP income statement (TTM) | |
|---|---|
| Revenue | kr.6.08m |
| Cost of Revenue | kr.0 |
| Gross Profit | kr.6.08m |
| Other Expenses | kr.6.55m |
| Earnings | -kr.462.19k |
Last Reported Earnings
Dec 31, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BRAINP perform over the long term?
See historical performance and comparison